We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-15.46%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$761M
AUM Growth
+$81M
Cap. Flow
+$243M
Cap. Flow %
31.93%
Top 10 Hldgs %
59.91%
Holding
63
New
13
Increased
16
Reduced
15
Closed
13

Top Buys

1
NVRO
NEVRO CORP.
NVRO
+$33.1M
2
DXCM icon
DexCom
DXCM
+$19.8M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$19.4M
4
ADMS
Adamas Pharmaceuticals
ADMS
+$16.7M
5
TSRO
TESARO, Inc.
TSRO
+$16.2M

Top Sells

1
CORI
Corium International, Inc.
CORI
+$22.5M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$17.1M
3
PACB icon
Pacific Biosciences
PACB
+$13.5M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$11.8M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.04M

Sector Composition

1 Healthcare 55.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$175M 23%
+700,000
New +$189M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$2.23B
$52.7M 6.93%
5,951,153
+1,056,792
+22% +$10.2M
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$50.2M 6.6%
700,000
+540,000
+338% +$43.5M
TSRO
4
DELISTED
TESARO, Inc.
TSRO
$32.8M 4.32%
442,219
+337,519
+322% +$16.2M
NVRO
5
DELISTED
NEVRO CORP.
NVRO
$28.9M 3.81%
+744,415
New +$33.1M
PETX
6
DELISTED
Aratana Therapeutics, Inc.
PETX
$25M 3.29%
4,083,135
– –
TSRO
7
CALL
DELISTED
TESARO, Inc.
TSRO
$24.1M 3.17%
325,000
+200,000
+160% +$9.61M
TVTX icon
8
Travere Therapeutics
TVTX
$5.27B
$23M 3.02%
1,016,114
+77,900
+8% +$1.94M
ADMS
9
DELISTED
Adamas Pharmaceuticals
ADMS
$22.3M 2.94%
2,614,468
+1,286,044
+97% +$16.7M
DXCM icon
10
DexCom
DXCM
$29.6B
$21.6M 2.83%
719,600
+622,800
+643% +$19.8M
ZGNX
11
DELISTED
Zogenix, Inc.
ZGNX
$19.5M 2.57%
535,998
-121,900
-19% -$4.99M
LJPC
12
DELISTED
La Jolla Pharmaceutical Company
LJPC
$18.4M 2.41%
1,947,541
-106,450
-5% -$1.6M
BDSI
13
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$16.2M 2.13%
4,375,066
– –
SCTL
14
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$14.5M 1.91%
2,283,548
– –
GBT
15
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$14.4M 1.89%
350,000
+200,000
+133% +$7.49M
ACRS icon
16
Aclaris Therapeutics
ACRS
$793M
$13.9M 1.82%
+1,877,502
New +$19.4M
SBBP
17
DELISTED
Strongbridge Biopharma plc.
SBBP
$12.6M 1.66%
2,821,722
+258,626
+10% +$1.26M
CPRX icon
18
Catalyst Pharmaceutical
CPRX
$12M 1.58%
6,268,298
+1,132,034
+22% +$3.24M
NVRO
19
CALL
DELISTED
NEVRO CORP.
NVRO
$11.7M 1.53%
+300,000
New +$13.3M
INCY icon
20
Incyte
INCY
$23.4B
$11.7M 1.53%
+183,300
New +$11.9M
NSTG
21
DELISTED
NanoString Technologies, Inc.
NSTG
$10.7M 1.41%
720,600
-129,400
-15% -$2.05M
QTNT
22
DELISTED
Quotient Limited Ordinary Shares
QTNT
$10.4M 1.37%
42,440
+22,322
+111% +$5.85M
ADMA icon
23
ADMA Biologics
ADMA
$2.02B
$10.1M 1.33%
4,226,077
-237,752
-5% -$1.18M
GBT
24
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.89M 1.3%
+240,909
New +$9.03M
ATRS
25
DELISTED
Antares Pharma, Inc.
ATRS
$9.37M 1.23%
3,444,147
-1,179,100
-26% -$3.88M
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Broadfin Capital held 63 positions worth $761M, up 12% from $680M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Broadfin Capital deployed $243M of net new capital in Q4 2018, opening 13 new positions and adding to 16 existing holdings. Its largest new stake was NEVRO CORP.: 744,415 shares worth $28.9M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 73% a quarter earlier.

On the sell side, the largest reduction was Tandem Diabetes Care, an estimated $17.1M trimmed.

  • Broadfin Capital's largest Q4 2018 buy was NEVRO CORP.: 744,415 shares worth $28.9M.
  • Broadfin Capital added most to DexCom in Q4 2018, an estimated $19.8M increase.
  • Broadfin Capital's biggest Q4 2018 reduction was Tandem Diabetes Care, cutting an estimated $17.1M.
  • Broadfin Capital fully exited Corium International, Inc. in Q4 2018, selling an estimated $22.5M.
  • Broadfin Capital's ten largest holdings make up 60% of its $761M portfolio in Q4 2018.
  • Broadfin Capital opened 13 new positions and closed 13 in Q4 2018.
  • Broadfin Capital's portfolio value rose 12% quarter-over-quarter to $761M.

Based on Broadfin Capital's 13F filing for Q4 2018, filed 14 Feb 2019.